In the news recently, an experimental vaccine can provide long-term protection against prostate cancer in mice genetically predisposed to the disease, new research indicates.
"By early vaccination, we have basically given these mice life-long protection against a disease they were destined to have," senior investigator Dr. W. Martin Kast, from the University of Southern California in Los Angeles, said in a statement.
"This has never been done before and, with further research, could represent a paradigm shift in the management of human prostate cancer."
A Food and Drug Administration (FDA) advisory panel announced the new treatment designed to turn the body's own immune system against deadly prostate cancer tumors is both safe and effective.
Last week it was announced, more than half of men with metastatic, hormone-refractory prostate cancer had longer-than-estimated survival after treatment with an adenovirus/PSA vaccine, showed a phase I study.
<?XML:NAMESPACE PREFIX = O />
About half the patients had increased PSA doubling time and about 70% had anti-PSA T-cell responses associated with tumor destruction, reported David Lubaroff, Ph.D., of the University of Iowa in Iowa City. No patient had a vaccine-related adverse event.
This is exciting news for men!
Dr. Dominic Gaziano - Dr. G The Feel Good Health Guy / Health & Wellness Expert